Developmental toxicity testing for safety assessment: new approaches and technologies
Thomas B Knudsen1, Robert J Kavlock, George P Daston
1National Center for Computational Toxicology, US Environmental Protection Agency, Research Triangle Park, North Carolina 27711, USA. knudsen.thomas@epa.gov
Summary
New technologies are emerging for developmental toxicology assessment to evaluate the vast number of chemicals needing hazard data. These innovative methods aim to improve safety evaluations beyond traditional animal studies.
Area of Science:
- Toxicology
- Developmental Biology
- Genomics
- Computational Biology
Background:
- Traditional animal studies are insufficient for assessing the developmental toxicity of the 10,000-30,000 chemicals in commerce.
- There is a critical need for alternative technologies to evaluate developmental toxicity risks.
- Advancements in various scientific fields offer potential solutions for developmental safety assessment.
Purpose of the Study:
- To review novel approaches and technologies for assessing developmental toxicology.
- To explore the application of new methods in developmental safety assessment.
- To address the challenges and needs in utilizing alternative technologies for chemical hazard evaluation.
Main Methods:
- Genomics technologies for developmental safety assessment.
- Mouse embryonic stem cells for capturing developmental toxicity pathway data.
- Dynamical cell imaging of zebrafish embryos.
- Computational models of developmental pathways and systems.
- High-throughput in vitro approaches (e.g., EPA ToxCast program).
Main Results:
- Overview of diverse new technologies applicable to developmental toxicology.
- Identification of challenges in translating in vitro findings to in vivo relevance.
- Emphasis on the necessity of validating pathway-based predictions with whole-animal studies.
- Demonstration of progress towards evaluating a large chemical inventory.
Conclusions:
- New technologies are crucial for addressing the limitations of traditional developmental toxicity testing.
- Integrating genomics, stem cell assays, imaging, computational models, and high-throughput screening shows promise.
- Validation and careful application of these methods are essential for accurate developmental risk assessment.
Related Concept Videos
Toxicokinetics: Overview
97
Studies that assess how a drug is absorbed, distributed, metabolized, and excreted (ADME) at toxic doses are termed toxicokinetics. Understanding toxicokinetics helps predict adverse drug reactions (ADRs) and manage toxicity in humans.Toxicokinetics differs from pharmacokinetics mainly in the dose levels studied, with toxicokinetics focusing on higher toxic doses. The kinetics at these levels can be non-linear due to altered physiological processes. Toxicodynamics examines the relationship...
97
Toxicity Testing in Animals
65
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
65
In Vitro Drug Release Testing: Overview, Development and Validation
440
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
440
Preclinical Development: Overview
6.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.2K
Mutagenicity and Carcinogenicity
2.1K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.1K


